
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10504020/publications.pdf Version: 2024-02-01



KUN-LIANG GUAN

#	Article	IF	CITATIONS
1	The two sides of Hippo pathway in cancer. Seminars in Cancer Biology, 2022, 85, 33-42.	9.6	34
2	Coâ€occurrence of <i>BAP1</i> and <i>SF3B1</i> mutations in uveal melanoma induces cellular senescence. Molecular Oncology, 2022, 16, 607-629.	4.6	12
3	Protocols for measuring phosphorylation, subcellular localization, and kinase activity of Hippo pathway components YAP and LATS in cultured cells. STAR Protocols, 2022, 3, 101102.	1.2	0
4	Transcriptional repression of estrogen receptor alpha by YAP reveals the Hippo pathway as therapeutic target for ER+ breast cancer. Nature Communications, 2022, 13, 1061.	12.8	55
5	Itaconate inhibits TET DNA dioxygenases to dampen inflammatory responses. Nature Cell Biology, 2022, 24, 353-363.	10.3	67
6	Rheb regulates nuclear mTORC1 activity independent of farnesylation. Cell Chemical Biology, 2022, 29, 1037-1045.e4.	5.2	6
7	The multifaceted role of autophagy in cancer. EMBO Journal, 2022, 41, e110031.	7.8	63
8	The Hippo pathway mediates Semaphorin signaling. Science Advances, 2022, 8, .	10.3	6
9	Hippo pathway regulation by phosphatidylinositol transfer protein and phosphoinositides. Nature Chemical Biology, 2022, 18, 1076-1086.	8.0	12
10	Hippo Signaling in Embryogenesis and Development. Trends in Biochemical Sciences, 2021, 46, 51-63.	7.5	118
11	Structural insights into TSC complex assembly and GAP activity on Rheb. Nature Communications, 2021, 12, 339.	12.8	44
12	Hippo signalling maintains ER expression and ER+ breast cancer growth. Nature, 2021, 591, E1-E10.	27.8	38
13	YAP plays a crucial role in the development of cardiomyopathy in lysosomal storage diseases. Journal of Clinical Investigation, 2021, 131, .	8.2	29
14	Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth. Genes and Development, 2020, 34, 72-86.	5.9	68
15	TAZ Represses the Neuronal Commitment of Neural Stem Cells. Cells, 2020, 9, 2230.	4.1	9
16	Heat stress activates YAP/TAZ to induce the heat shock transcriptome. Nature Cell Biology, 2020, 22, 1447-1459.	10.3	56
17	The Zscan4-Tet2 Transcription Nexus Regulates Metabolic Rewiring and Enhances Proteostasis to Promote Reprogramming. Cell Reports, 2020, 32, 107877.	6.4	22
18	Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nature Reviews Drug Discovery, 2020, 19, 480-494.	46.4	396

#	Article	IF	CITATIONS
19	YAP/TAZ phase separation for transcription. Nature Cell Biology, 2020, 22, 357-358.	10.3	24
20	Critical roles of phosphoinositides and NF2 in Hippo pathway regulation. Genes and Development, 2020, 34, 511-525.	5.9	39
21	Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 969-986.e7.	16.2	117
22	EIF3H Orchestrates Hippo Pathway–Mediated Oncogenesis via Catalytic Control of YAP Stability. Cancer Research, 2020, 80, 2550-2563.	0.9	24
23	The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis. Cell Death and Disease, 2019, 10, 755.	6.3	46
24	Amino Acids License Kinase mTORC1 Activity and Treg Cell Function via Small G Proteins Rag and Rheb. Immunity, 2019, 51, 1012-1027.e7.	14.3	76
25	Volume Adaptation Controls Stem Cell Mechanotransduction. ACS Applied Materials & Interfaces, 2019, 11, 45520-45530.	8.0	57
26	Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation. Blood, 2019, 134, 1730-1744.	1.4	17
27	YAP and TAZ regulate cell volume. Journal of Cell Biology, 2019, 218, 3472-3488.	5.2	39
28	BRCA1/BARD1-dependent ubiquitination of NF2 regulates Hippo-YAP1 signaling. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7363-7370.	7.1	17
29	mTORC1 underlies ageâ€related muscle fiber damage and loss by inducing oxidative stress and catabolism. Aging Cell, 2019, 18, e12943.	6.7	104
30	SIRT5 deficiency suppresses mitochondrial ATP production and promotes AMPK activation in response to energy stress. PLoS ONE, 2019, 14, e0211796.	2.5	40
31	STRIPAK integrates upstream signals to initiate the Hippo kinase cascade. Nature Cell Biology, 2019, 21, 1565-1577.	10.3	98
32	Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry. Laboratory Investigation, 2019, 99, 588-598.	3.7	16
33	mTOR as a central hub of nutrient signalling and cell growth. Nature Cell Biology, 2019, 21, 63-71.	10.3	698
34	Determining the Phosphorylation Status of Hippo Components YAP and TAZ Using Phos-tag. Methods in Molecular Biology, 2019, 1893, 281-287.	0.9	7
35	The Hippo Pathway: Biology and Pathophysiology. Annual Review of Biochemistry, 2019, 88, 577-604.	11.1	708
36	OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ. Molecular Cell, 2019, 73, 7-21.e7.	9.7	112

#	Article	IF	CITATIONS
37	Cell type-dependent function of LATS1/2 in cancer cell growth. Oncogene, 2019, 38, 2595-2610.	5.9	29
38	GPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor. ELife, 2019, 8, .	6.0	60
39	Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates. Trends in Cancer, 2018, 4, 151-165.	7.4	160
40	Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis. Nature Communications, 2018, 9, 508.	12.8	127
41	Colonic epithelium rejuvenation through <scp>YAP</scp> / <scp>TAZ</scp> . EMBO Journal, 2018, 37, 164-166.	7.8	3
42	Deregulation and Therapeutic Potential of the Hippo Pathway in Cancer. Annual Review of Cancer Biology, 2018, 2, 59-79.	4.5	14
43	SNIP1 Recruits TET2 to Regulate c-MYC Target Genes and Cellular DNA Damage Response. Cell Reports, 2018, 25, 1485-1500.e4.	6.4	63
44	Regulation of the Hippo Pathway by Phosphatidic Acid-Mediated Lipid-Protein Interaction. Molecular Cell, 2018, 72, 328-340.e8.	9.7	74
45	Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells. Cell Reports, 2018, 25, 1018-1026.e4.	6.4	56
46	The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell. Journal of Biological Chemistry, 2018, 293, 11230-11240.	3.4	164
47	Interplay between YAP/TAZ and Metabolism. Cell Metabolism, 2018, 28, 196-206.	16.2	281
48	RAP2 mediates mechanoresponses of the Hippo pathway. Nature, 2018, 560, 655-660.	27.8	266
49	YAP and MRTF-A, transcriptional co-activators of RhoA-mediated gene expression, are critical for glioblastoma tumorigenicity. Oncogene, 2018, 37, 5492-5507.	5.9	49
50	Polycystic kidney disease: a Hippo connection. Genes and Development, 2018, 32, 737-739.	5.9	20
51	MTORC1-mediated NRBF2 phosphorylation functions as a switch for the class III PtdIns3K and autophagy. Autophagy, 2017, 13, 592-607.	9.1	71
52	<i>L2hgdh</i> Deficiency Accumulates <scp>l</scp> -2-Hydroxyglutarate with Progressive Leukoencephalopathy and Neurodegeneration. Molecular and Cellular Biology, 2017, 37, .	2.3	27
53	YAP–IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1643-1648.	7.1	85
54	Endothelin Promotes Colorectal Tumorigenesis by Activating YAP/TAZ. Cancer Research, 2017, 77, 2413-2423.	0.9	63

#	Article	IF	CITATIONS
55	Hippo signalling governs cytosolic nucleic acid sensing through YAP/TAZ-mediated TBK1 blockade. Nature Cell Biology, 2017, 19, 362-374.	10.3	153
56	elF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth. Cancer Research, 2017, 77, 1997-2007.	0.9	57
57	Osmotic stressâ€induced phosphorylation by <scp>NLK</scp> at Ser128 activates <scp>YAP</scp> . EMBO Reports, 2017, 18, 72-86.	4.5	112
58	Regulation of the Hippo Pathway Transcription Factor TEAD. Trends in Biochemical Sciences, 2017, 42, 862-872.	7.5	218
59	CLOCK Acetylates ASS1 to Drive Circadian Rhythm of Ureagenesis. Molecular Cell, 2017, 68, 198-209.e6.	9.7	53
60	<scp>SIRT</scp> 7 deacetylates <scp>DDB</scp> 1 and suppresses the activity of the <scp>CRL</scp> 4 E3 ligase complexes. FEBS Journal, 2017, 284, 3619-3636.	4.7	12
61	Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation. Nature Cell Biology, 2017, 19, 996-1002.	10.3	153
62	Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma. Cancer Cell, 2017, 32, 856-868.e5.	16.8	121
63	DNA–PK facilitates <i>piggyBac</i> transposition by promoting paired-end complex formation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 7408-7413.	7.1	16
64	The Hippo pathway in organ development, homeostasis, and regeneration. Current Opinion in Cell Biology, 2017, 49, 99-107.	5.4	176
65	Non-radioactive LATS in vitro Kinase Assay. Bio-protocol, 2017, 7, .	0.4	7
66	Thromboxane A2 Activates YAP/TAZ Protein to Induce Vascular Smooth Muscle Cell Proliferation and Migration. Journal of Biological Chemistry, 2016, 291, 18947-18958.	3.4	88
67	The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity. Cell, 2016, 167, 1525-1539.e17.	28.9	318
68	Characterization of Hippo Pathway Components by Gene Inactivation. Molecular Cell, 2016, 64, 993-1008.	9.7	219
69	Glycoholics Anonymous: Cancer Sobers Up with mTORC1. Cancer Cell, 2016, 29, 432-434.	16.8	2
70	The Hippo pathway in intestinal regeneration and disease. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 324-337.	17.8	204
71	Mst1 shuts off cytosolic antiviral defense through IRF3 phosphorylation. Genes and Development, 2016, 30, 1086-1100.	5.9	68
72	Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis. Proceedings of the Vational Academy of Sciences of the United States of America, 2016, 113, 11525-11530.	7.1	323

#	Article	IF	CITATIONS
73	Destabilization of Fatty Acid Synthase by Acetylation Inhibits <i>De Novo</i> Lipogenesis and Tumor Cell Growth. Cancer Research, 2016, 76, 6924-6936.	0.9	92
74	<scp>SIRT</scp> 5 promotes <scp>IDH</scp> 2 desuccinylation and G6 <scp>PD</scp> deglutarylation to enhance cellular antioxidant defense. EMBO Reports, 2016, 17, 811-822.	4.5	210
75	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
76	Mechanisms of Hippo pathway regulation. Genes and Development, 2016, 30, 1-17.	5.9	1,224
77	Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Reports, 2015, 13, 2353-2361.	6.4	153
78	<scp>PARD</scp> 3 induces <scp>TAZ</scp> activation and cell growth by promoting <scp>LATS</scp> 1 and <scp>PP</scp> 1 interaction. EMBO Reports, 2015, 16, 975-985.	4.5	46
79	Insulin and mTOR Pathway Regulate HDAC3-Mediated Deacetylation and Activation of PGK1. PLoS Biology, 2015, 13, e1002243.	5.6	72
80	Netrin-1 exerts oncogenic activities through enhancing Yes-associated protein stability. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7255-7260.	7.1	34
81	YAP and TAZ: a nexus for Hippo signaling and beyond. Trends in Cell Biology, 2015, 25, 499-513.	7.9	445
82	YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations. Molecular and Cellular Oncology, 2015, 2, e970957.	0.7	18
83	Differential regulation of mTORC1 by leucine and glutamine. Science, 2015, 347, 194-198.	12.6	585
84	Micro(RNA) Managing by mTORC1. Molecular Cell, 2015, 57, 575-576.	9.7	6
85	WT1 Recruits TET2 to Regulate Its Target Gene Expression and Suppress Leukemia Cell Proliferation. Molecular Cell, 2015, 57, 662-673.	9.7	242
86	The emerging roles of YAP and TAZ in cancer. Nature Reviews Cancer, 2015, 15, 73-79.	28.4	928
87	A gp130–Src–YAP module links inflammation to epithelial regeneration. Nature, 2015, 519, 57-62.	27.8	528
88	Disease implications of the Hippo/YAP pathway. Trends in Molecular Medicine, 2015, 21, 212-222.	6.7	191
89	Opposing roles of conventional and novel PKC isoforms in Hippo-YAP pathway regulation. Cell Research, 2015, 25, 985-988.	12.0	54
90	Sestrin2 inhibits mTORC1 through modulation of GATOR complexes. Scientific Reports, 2015, 5, 9502.	3.3	137

#	Article	IF	CITATIONS
91	<scp>SIRT</scp> 3â€dependent <scp>GOT</scp> 2 acetylation status affects the malate–aspartate <scp>NADH</scp> shuttle activity and pancreatic tumor growth. EMBO Journal, 2015, 34, 1110-1125.	7.8	152
92	A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis. Genes and Development, 2015, 29, 1271-1284.	5.9	278
93	Estrogen regulates Hippo signaling via GPER in breast cancer. Journal of Clinical Investigation, 2015, 125, 2123-2135.	8.2	179
94	mTOR: a pharmacologic target for autophagy regulation. Journal of Clinical Investigation, 2015, 125, 25-32.	8.2	1,425
95	Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nature Cell Biology, 2015, 17, 500-510.	10.3	421
96	The Hippo Pathway in Heart Development, Regeneration, and Diseases. Circulation Research, 2015, 116, 1431-1447.	4.5	178
97	The SIN1-PH Domain Connects mTORC2 to PI3K. Cancer Discovery, 2015, 5, 1127-1129.	9.4	44
98	Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell, 2015, 163, 811-828.	28.9	1,716
99	Atg5-independent autophagy regulates mitochondrial clearance and is essential for iPSC reprogramming. Nature Cell Biology, 2015, 17, 1379-1387.	10.3	153
100	Alternative Wnt Signaling Activates YAP/TAZ. Cell, 2015, 162, 780-794.	28.9	528
101	Class III PI3K regulates organismal glucose homeostasis by providing negative feedback on hepatic insulin signalling. Nature Communications, 2015, 6, 8283.	12.8	47
102	MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nature Communications, 2015, 6, 8357.	12.8	388
103	AMPK and autophagy in glucose/glycogen metabolism. Molecular Aspects of Medicine, 2015, 46, 46-62.	6.4	175
104	The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1. Cell Research, 2015, 25, 1299-1313.	12.0	164
105	NLK phosphorylates Raptor to mediate stress-induced mTORC1 inhibition. Genes and Development, 2015, 29, 2362-2376.	5.9	37
106	Hippo Pathway Regulation of Gastrointestinal Tissues. Annual Review of Physiology, 2015, 77, 201-227.	13.1	103
107	D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth. Oncotarget, 2015, 6, 8606-8620.	1.8	46
108	mTORC1 Promotes Denervation-Induced Muscle Atrophy Through a Mechanism Involving the Activation of FoxO and E3 Ubiquitin Ligases. Science Signaling, 2014, 7, ra18.	3.6	98

#	Article	IF	CITATIONS
109	Sestrins Inhibit mTORC1 Kinase Activation through the GATOR Complex. Cell Reports, 2014, 9, 1281-1291.	6.4	273
110	Both Decreased and Increased SRPK1 Levels Promote Cancer by Interfering with PHLPP-Mediated Dephosphorylation of Akt. Molecular Cell, 2014, 54, 378-391.	9.7	105
111	The Hippo signaling pathway in stem cell biology and cancer. EMBO Reports, 2014, 15, 642-656.	4.5	532
112	Oxidative Stress Activates SIRT2 to Deacetylate and Stimulate Phosphoglycerate Mutase. Cancer Research, 2014, 74, 3630-3642.	0.9	124
113	Clyceraldehyde-3-phosphate Dehydrogenase Is Activated by Lysine 254 Acetylation in Response to Glucose Signal. Journal of Biological Chemistry, 2014, 289, 3775-3785.	3.4	79
114	Autophagy regulation by nutrient signaling. Cell Research, 2014, 24, 42-57.	12.0	601
115	Transcription and processing: multilayer controls of RNA biogenesis by the Hippo pathway. EMBO Journal, 2014, 33, 942-944.	7.8	9
116	Rag GTPases are cardioprotective by regulating lysosomal function. Nature Communications, 2014, 5, 4241.	12.8	73
117	Hippo Pathway Key to Ploidy Checkpoint. Cell, 2014, 158, 695-696.	28.9	3
118	An alternative DNA damage pathway to apoptosis in hematological cancers. Nature Medicine, 2014, 20, 587-588.	30.7	5
119	Regulation of G6PD acetylation by KAT9/SIRT2 modulates NADPH homeostasis and cell survival during oxidative stress. EMBO Journal, 2014, 33, 1304-20.	7.8	205
120	Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP. Cancer Cell, 2014, 25, 822-830.	16.8	391
121	YAP as oncotarget in uveal melanoma. Oncoscience, 2014, 1, 480-481.	2.2	14
122	LATS2 Suppresses Oncogenic Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction. Cell Reports, 2013, 5, 1650-1663.	6.4	69
123	Regulation of the Hippo pathway and implications for anticancer drug development. Trends in Pharmacological Sciences, 2013, 34, 581-589.	8.7	100
124	Regulation of PIK3C3/VPS34 complexes by MTOR in nutrient stress-induced autophagy. Autophagy, 2013, 9, 1983-1995.	9.1	249
125	Acetylation Stabilizes ATP-Citrate Lyase to Promote Lipid Biosynthesis and Tumor Growth. Molecular Cell, 2013, 51, 506-518.	9.7	291
126	Phosphorylation of Angiomotin by Lats1/2 Kinases Inhibits F-actin Binding, Cell Migration, and Angiogenesis. Journal of Biological Chemistry, 2013, 288, 34041-34051.	3.4	133

#	Article	IF	CITATIONS
127	Differential Regulation of Distinct Vps34 Complexes by AMPK in Nutrient Stress and Autophagy. Cell, 2013, 152, 290-303.	28.9	646
128	Mitogenic and Oncogenic Stimulation of K433 Acetylation Promotes PKM2 Protein Kinase Activity and Nuclear Localization. Molecular Cell, 2013, 52, 340-352.	9.7	246
129	Amino acid signalling upstream of mTOR. Nature Reviews Molecular Cell Biology, 2013, 14, 133-139.	37.0	716
130	The Hippo pathway: regulators and regulations. Genes and Development, 2013, 27, 355-371.	5.9	1,034
131	R-2-Hydroxyglutarate as the Key Effector of IDH Mutations Promoting Oncogenesis. Cancer Cell, 2013, 23, 274-276.	16.8	77
132	Nutrient signaling to mTOR and cell growth. Trends in Biochemical Sciences, 2013, 38, 233-242.	7.5	327
133	Lysine-5 Acetylation Negatively Regulates Lactate Dehydrogenase A and Is Decreased in Pancreatic Cancer. Cancer Cell, 2013, 23, 464-476.	16.8	257
134	Regulation of YAP and TAZ Transcription Co-activators. , 2013, , 71-87.		2
135	Nutrient Sensing, Metabolism, and Cell Growth Control. Molecular Cell, 2013, 49, 379-387.	9.7	285
136	ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase. Nature Cell Biology, 2013, 15, 741-750.	10.3	1,255
137	Defects of Vps15 in skeletal muscles lead to autophagic vacuolar myopathy and lysosomal disease. EMBO Molecular Medicine, 2013, 5, 870-890.	6.9	96
138	Microtubule-associated Protein/Microtubule Affinity-regulating Kinase 4 (MARK4) Is a Negative Regulator of the Mammalian Target of Rapamycin Complex 1 (mTORC1). Journal of Biological Chemistry, 2013, 288, 703-708.	3.4	64
139	Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation. Genes and Development, 2013, 27, 1223-1232.	5.9	269
140	A Critical Role for <i>Rictor</i> in T Lymphopoiesis. Journal of Immunology, 2012, 189, 1850-1857.	0.8	42
141	Down Syndrome Cell Adhesion Molecule (DSCAM) Associates with Uncoordinated-5C (UNC5C) in Netrin-1-mediated Growth Cone Collapse. Journal of Biological Chemistry, 2012, 287, 27126-27138.	3.4	57
142	Regulation of the Hippo–YAP pathway by protease-activated receptors (PARs). Genes and Development, 2012, 26, 2138-2143.	5.9	239
143	Elite control of HIV: p21 (waf-1/cip-1) at its best. Cell Cycle, 2012, 11, 4097-4098.	2.6	32
144	Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes and Development, 2012, 26, 54-68.	5.9	632

#	Article	IF	CITATIONS
145	The N-terminal Phosphodegron Targets TAZ/WWTR1 Protein for SCFÎ ² -TrCP-dependent Degradation in Response to Phosphatidylinositol 3-Kinase Inhibition. Journal of Biological Chemistry, 2012, 287, 26245-26253.	3.4	134
146	Temporal Changes in PTEN and mTORC2 Regulation of Hematopoietic Stem Cell Self-Renewal and Leukemia Suppression. Cell Stem Cell, 2012, 11, 415-428.	11.1	177
147	Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling. Cell, 2012, 150, 780-791.	28.9	1,310
148	<i>IDH1</i> and <i>IDH2</i> Mutations in Tumorigenesis: Mechanistic Insights and Clinical Perspectives. Clinical Cancer Research, 2012, 18, 5562-5571.	7.0	341
149	Mechanistic insights into the regulation of metabolic enzymes by acetylation. Journal of Cell Biology, 2012, 198, 155-164.	5.2	202
150	Alterations of metabolic genes and metabolites in cancer. Seminars in Cell and Developmental Biology, 2012, 23, 370-380.	5.0	100
151	Acetylation Negatively Regulates Glycogen Phosphorylase by Recruiting Protein Phosphatase 1. Cell Metabolism, 2012, 15, 75-87.	16.2	110
152	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
153	The YAP and TAZ transcription co-activators: Key downstream effectors of the mammalian Hippo pathway. Seminars in Cell and Developmental Biology, 2012, 23, 785-793.	5.0	397
154	YAP mediates crosstalk between the Hippo and PI(3)K–TOR pathways by suppressing PTEN viaÂmiR-29. Nature Cell Biology, 2012, 14, 1322-1329.	10.3	392
155	AMPK and mTOR in Cellular Energy Homeostasis and Drug Targets. Annual Review of Pharmacology and Toxicology, 2012, 52, 381-400.	9.4	650
156	The mechanisms of IDH mutations in tumorigenesis. Cell Research, 2012, 22, 1102-1104.	12.0	32
157	Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes and Development, 2012, 26, 1326-1338.	5.9	855
158	The Vam6-Gtr1/Gtr2 pathway activates TORC1 in response to amino acids in fission yeast. Journal of Cell Science, 2012, 125, 1920-8.	2.0	52
159	Organ Size Control by Hippo and TOR Pathways. Current Biology, 2012, 22, R368-R379.	3.9	167
160	An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development (Cambridge), 2011, 138, 3343-3356.	2.5	123
161	The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nature Cell Biology, 2011, 13, 877-883.	10.3	1,009
162	Amino Acid Signaling in TOR Activation. Annual Review of Biochemistry, 2011, 80, 1001-1032.	11.1	202

#	Article	IF	CITATIONS
163	Sirt3 Promotes the Urea Cycle and Fatty Acid Oxidation during Dietary Restriction. Molecular Cell, 2011, 41, 139-149.	9.7	344
164	Acetylation Targets the M2 Isoform of Pyruvate Kinase for Degradation through Chaperone-Mediated Autophagy and Promotes Tumor Growth. Molecular Cell, 2011, 42, 719-730.	9.7	479
165	Acetylation Regulates Gluconeogenesis by Promoting PEPCK1 Degradation via Recruiting the UBR5ÂUbiquitin Ligase. Molecular Cell, 2011, 43, 33-44.	9.7	331
166	Regulation of the autophagy initiating kinase ULK1 by nutrients: Roles of mTORC1 and AMPK. Cell Cycle, 2011, 10, 1337-1338.	2.6	81
167	mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. Journal of Clinical Investigation, 2011, 121, 2181-2196.	8.2	462
168	AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nature Cell Biology, 2011, 13, 132-141.	10.3	5,447
169	Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1. Nature Cell Biology, 2011, 13, 263-272.	10.3	128
170	Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO Reports, 2011, 12, 534-541.	4.5	468
171	Regulation of intermediary metabolism by protein acetylation. Trends in Biochemical Sciences, 2011, 36, 108-116.	7.5	323
172	Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases. Cancer Cell, 2011, 19, 17-30.	16.8	2,340
173	lκB kinase Îμ and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 6474-6479.	7.1	195
174	Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes and Development, 2011, 25, 51-63.	5.9	557
175	mTOR in podocyte function. Cell Cycle, 2011, 10, 3415-3416.	2.6	24
176	The Tuberous Sclerosis Complex–Mammalian Target of Rapamycin Pathway Maintains the Quiescence and Survival of Naive T Cells. Journal of Immunology, 2011, 187, 1106-1112.	0.8	80
177	PP1 Cooperates with ASPP2 to Dephosphorylate and Activate TAZ. Journal of Biological Chemistry, 2011, 286, 5558-5566.	3.4	120
178	Redox Regulates Mammalian Target of Rapamycin Complex 1 (mTORC1) Activity by Modulating the TSC1/TSC2-Rheb GTPase Pathway. Journal of Biological Chemistry, 2011, 286, 32651-32660.	3.4	123
179	Crystal structure of the Gtr1p–Gtr2p complex reveals new insights into the amino acid-induced TORC1 activation. Genes and Development, 2011, 25, 1668-1673.	5.9	93
180	The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR. Autophagy, 2011, 7, 643-644.	9.1	508

#	Article	IF	CITATIONS
181	Generation of acetyllysine antibodies and affinity enrichment of acetylated peptides. Nature Protocols, 2010, 5, 1583-1595.	12.0	89
182	Regulation of Integrin \hat{l}^21 Recycling to Lipid Rafts by Rab1a to Promote Cell Migration. Journal of Biological Chemistry, 2010, 285, 29398-29405.	3.4	90
183	Hippo signaling at a glance. Journal of Cell Science, 2010, 123, 4001-4006.	2.0	107
184	The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCFÎ ² -TrCP E3 Ligase. Journal of Biological Chemistry, 2010, 285, 37159-37169.	3.4	422
185	Regulation of mTORC1 by the Rab and Arf GTPases. Journal of Biological Chemistry, 2010, 285, 19705-19709.	3.4	120
186	The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes and Development, 2010, 24, 1106-1118.	5.9	621
187	Structural insights into the YAP and TEAD complex. Genes and Development, 2010, 24, 235-240.	5.9	310
188	The Hippo–YAP pathway in organ size control and tumorigenesis: an updated version. Genes and Development, 2010, 24, 862-874.	5.9	978
189	A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF ^{β-TRCP} . Genes and Development, 2010, 24, 72-85.	5.9	1,100
190	ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4153-4158.	7.1	628
191	IDH1 mutant structures reveal a mechanism of dominant inhibition. Cell Research, 2010, 20, 1279-1281.	12.0	24
192	Regulation of Cellular Metabolism by Protein Lysine Acetylation. Science, 2010, 327, 1000-1004.	12.6	1,642
193	Rag GTPases in TORC1 Activation and Nutrient Signaling. The Enzymes, 2010, 27, 75-87.	1.7	1
194	Acetylation of Metabolic Enzymes Coordinates Carbon Source Utilization and Metabolic Flux. Science, 2010, 327, 1004-1007.	12.6	924
195	MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. Journal of Clinical Investigation, 2010, 120, 2805-2816.	8.2	291
196	Rheb controls misfolded protein metabolism by inhibiting aggresome formation and autophagy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8923-8928.	7.1	88
197	TEAD Transcription Factors Mediate the Function of TAZ in Cell Growth and Epithelial-Mesenchymal Transition. Journal of Biological Chemistry, 2009, 284, 13355-13362.	3.4	470
198	Lysine 88 Acetylation Negatively Regulates Ornithine Carbamoyltransferase Activity in Response to Nutrient Signals. Journal of Biological Chemistry, 2009, 284, 13669-13675.	3.4	55

#	Article	IF	CITATIONS
199	RAC GTPases in nutrient-mediated TOR signaling pathway. Cell Cycle, 2009, 8, 1014-1018.	2.6	34
200	Both TEAD-Binding and WW Domains Are Required for the Growth Stimulation and Oncogenic Transformation Activity of Yes-Associated Protein. Cancer Research, 2009, 69, 1089-1098.	0.9	175
201	Critical roles for the TSC-mTOR pathway in β-cell function. American Journal of Physiology - Endocrinology and Metabolism, 2009, 297, E1013-E1022.	3.5	88
202	Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. Human Molecular Genetics, 2009, 18, R94-R100.	2.9	89
203	Mst Out and HCC In. Cancer Cell, 2009, 16, 363-364.	16.8	28
204	Harness the Power: New Insights into the Inhibition of YAP/ Yorkie. Developmental Cell, 2009, 16, 321-322.	7.0	8
205	Critical Role for Hypothalamic mTOR Activity in Energy Balance. Cell Metabolism, 2009, 9, 362-374.	16.2	164
206	The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochemical and Biophysical Research Communications, 2009, 384, 471-475.	2.1	150
207	Amino Acid Signaling to TOR Activation: Vam6 Functioning as a Gtr1 GEF. Molecular Cell, 2009, 35, 543-545.	9.7	14
208	Glioma-Derived Mutations in <i>IDH1</i> Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α. Science, 2009, 324, 261-265.	12.6	1,014
209	Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO Journal, 2008, 27, 1919-1931.	7.8	567
210	Regulation of TORC1 by Rag GTPases in nutrient response. Nature Cell Biology, 2008, 10, 935-945.	10.3	1,143
211	The Hippo–YAP pathway: new connections between regulation of organ size and cancer. Current Opinion in Cell Biology, 2008, 20, 638-646.	5.4	400
212	Substrate Selectivity APPLies to Akt. Cell, 2008, 133, 399-400.	28.9	6
213	TSC–mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. Journal of Experimental Medicine, 2008, 205, 2397-2408.	8.5	615
214	A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. American Journal of Physiology - Cell Physiology, 2008, 295, C836-C843.	4.6	199
215	AMP-activated Protein Kinase Contributes to UV- and H2O2-induced Apoptosis in Human Skin Keratinocytes. Journal of Biological Chemistry, 2008, 283, 28897-28908.	3.4	100
216	TAZ Promotes Cell Proliferation and Epithelial-Mesenchymal Transition and Is Inhibited by the Hippo Pathway. Molecular and Cellular Biology, 2008, 28, 2426-2436.	2.3	805

#	Article	IF	CITATIONS
217	TEAD mediates YAP-dependent gene induction and growth control. Genes and Development, 2008, 22, 1962-1971.	5.9	1,943
218	TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. Journal of Cell Biology, 2008, 183, i1-i1.	5.2	0
219	Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes and Development, 2007, 21, 2747-2761.	5.9	2,487
220	Bnip3 Mediates the Hypoxia-induced Inhibition on Mammalian Target of Rapamycin by Interacting with Rheb. Journal of Biological Chemistry, 2007, 282, 35803-35813.	3.4	224
221	Adiponectin Sensitizes Insulin Signaling by Reducing p70 S6 Kinase-mediated Serine Phosphorylation of IRS-1. Journal of Biological Chemistry, 2007, 282, 7991-7996.	3.4	179
222	mTOR Pathway as a Target in Tissue Hypertrophy. Annual Review of Pharmacology and Toxicology, 2007, 47, 443-467.	9.4	162
223	Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO Journal, 2007, 26, 4812-4823.	7.8	153
224	Expanding mTOR signaling. Cell Research, 2007, 17, 666-681.	12.0	485
225	Muscle atrophy in transgenic mice expressing a human TSC1 transgene. FEBS Letters, 2006, 580, 5621-5627.	2.8	28
226	Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes and Development, 2006, 20, 2820-2832.	5.9	434
227	TSC1 Stabilizes TSC2 by Inhibiting the Interaction between TSC2 and the HERC1 Ubiquitin Ligase*. Journal of Biological Chemistry, 2006, 281, 8313-8316.	3.4	195
228	TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth. Cell, 2006, 126, 955-968.	28.9	1,183
229	Complexity of the TOR signaling network. Trends in Cell Biology, 2006, 16, 206-212.	7.9	176
230	Measurements of TSC2 GAP Activity Toward Rheb. Methods in Enzymology, 2006, 407, 46-54.	1.0	17
231	TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6811-6816.	7.1	169
232	Semaphorin 4D activates the MAPK pathway downstream of plexinâ€B1. FASEB Journal, 2006, 20, LB75.	0.5	0
233	Dysregulation of the TSC-mTOR pathway in human disease. Nature Genetics, 2005, 37, 19-24.	21.4	911
234	Semaphorins command cells to move. Nature Reviews Molecular Cell Biology, 2005, 6, 789-800.	37.0	444

#	Article	IF	CITATIONS
235	Signaling by Target of Rapamycin Proteins in Cell Growth Control. Microbiology and Molecular Biology Reviews, 2005, 69, 79-100.	6.6	296
236	The Stress-inducted Proteins RTP801 and RTP801L Are Negative Regulators of the Mammalian Target of Rapamycin Pathway. Journal of Biological Chemistry, 2005, 280, 9769-9772.	3.4	217
237	Identification of FIP200 interaction with the TSC1–TSC2 complex and its role in regulation of cell size control. Journal of Cell Biology, 2005, 170, 379-389.	5.2	78
238	Biochemical and Functional Characterizations of Small GTPase Rheb and TSC2 GAP Activity. Molecular and Cellular Biology, 2004, 24, 7965-7975.	2.3	226
239	Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes and Development, 2004, 18, 1533-1538.	5.9	481
240	TSC2: filling the GAP in the mTOR signaling pathway. Trends in Biochemical Sciences, 2004, 29, 32-38.	7.5	373
241	Mechanisms of regulating the Raf kinase family. Cellular Signalling, 2003, 15, 463-469.	3.6	356
242	Signalling mechanisms mediating neuronal responses to guidance cues. Nature Reviews Neuroscience, 2003, 4, 941-956.	10.2	267
243	TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival. Cell, 2003, 115, 577-590.	28.9	3,362
244	Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes and Development, 2003, 17, 1829-1834.	5.9	1,566
245	A Role for NF-κB Essential Modifier/IκB Kinase-γ (NEMO/IKKγ) Ubiquitination in the Activation of the IκB Kinase Complex by Tumor Necrosis Factor-α. Journal of Biological Chemistry, 2003, 278, 37297-37305.	3.4	191
246	Human homologue of <i>Drosophila</i> CNK interacts with Ras effector proteins Raf and Rlf ¹ . FASEB Journal, 2003, 17, 2048-2060.	0.5	53
247	The p38 and MK2 Kinase Cascade Phosphorylates Tuberin, the Tuberous Sclerosis 2 Gene Product, and Enhances Its Interaction with 14-3-3. Journal of Biological Chemistry, 2003, 278, 13663-13671.	3.4	143
248	The semaphorin receptor plexin-B1 signals through a direct interaction with the Rho-specific nucleotide exchange factor, LARG. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12085-12090.	7.1	152
249	Regulation of TSC2 by 14-3-3 Binding. Journal of Biological Chemistry, 2002, 277, 44593-44596.	3.4	99
250	The Plexin-B1/Rac interaction inhibits PAK activation and enhances Sema4D ligand binding. Genes and Development, 2002, 16, 836-845.	5.9	106
251	TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nature Cell Biology, 2002, 4, 648-657.	10.3	2,667

Regulation of the Ras-MAPK Pathway at the Level of Ras and Raf. , 2002, 24, 49-66.

2

#	Article	IF	CITATIONS
253	Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nature Genetics, 2001, 29, 25-33.	21.4	284
254	Function of the Rho Family GTPases in Ras-stimulated Raf Activation. Journal of Biological Chemistry, 2001, 276, 34728-34737.	3.4	67
255	Serum- and Glucocorticoid-inducible Kinase SCK Phosphorylates and Negatively Regulates B-Raf. Journal of Biological Chemistry, 2001, 276, 31620-31626.	3.4	92
256	The Dominant Negative Ras Mutant, N17Ras, Can Inhibit Signaling Independently of Blocking Ras Activation. Journal of Biological Chemistry, 2000, 275, 8854-8862.	3.4	38
257	Essential Functions of Protein Tyrosine Phosphatases Ptp2 and Ptp3 and Rim11 Tyrosine Phosphorylation in <i>Saccharomyces cerevisiae</i> Meiosis and Sporulation. Molecular Biology of the Cell, 2000, 11, 663-676.	2.1	33
258	Negative Regulation of the Serine/Threonine Kinase B-Raf by Akt. Journal of Biological Chemistry, 2000, 275, 27354-27359.	3.4	194
259	The leucine-rich repeat protein SUR-8 enhances MAP kinase activation and forms a complex with Ras and Raf. Genes and Development, 2000, 14, 895-900.	5.9	128
260	Negative Regulation of the Forkhead Transcription Factor FKHR by Akt. Journal of Biological Chemistry, 1999, 274, 16741-16746.	3.4	688
261	Kinase Suppressor of Ras Forms a Multiprotein Signaling Complex and Modulates MEK Localization. Molecular and Cellular Biology, 1999, 19, 5523-5534.	2.3	201
262	Differential effect of glucose deprivation on MAPK activation in drug sensitive human breast carcinoma MCF-7 and multidrug resistant MCF-7/ADR cells. Molecular and Cellular Biochemistry, 1997, 170, 23-30.	3.1	21
263	Inducible expression of a mutant form of MEK1 in Swiss 3T3 cells. , 1997, 67, 367-377.		6
264	Selective Activation of MEK1 but Not MEK2 by A-Raf from Epidermal Growth Factor-stimulated Hela Cells. Journal of Biological Chemistry, 1996, 271, 3265-3271.	3.4	104